Company Profile
Savara, Inc. Stock Price, News & Catalysts
- Ticker:
- SVRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.65 USD (-2.72%)
Close
Last updated: October 6, 2026
1.08B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, SVRA closed down 2.72% at $4.65. No new same-company headline was identified in the current news window.
Company overview
Rare Respiratory Disease Company
Savara is focused on developing and preparing to commercialize a treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which surfactant accumulates in the alveoli and progressively impairs gas exchange.
MOLBREEVI and Molgramostim
MOLBREEVI is the proposed brand name for molgramostim inhalation solution, a recombinant human granulocyte-macrophage colony-stimulating factor. The therapy is delivered directly to the lungs and is designed to restore signaling needed for alveolar macrophages to clear accumulated surfactant.
Autoimmune PAP Treatment Strategy
The program targets the underlying immune dysfunction in autoimmune pulmonary alveolar proteinosis rather than relying only on whole-lung lavage or other supportive interventions. The pivotal IMPALA-2 study evaluated effects on lung function, respiratory health, and disease burden.
Inhaled Delivery Platform
Molgramostim is administered with a dedicated nebulizer, combining a biologic drug with pulmonary delivery technology. This approach is intended to concentrate treatment in the lungs while supporting chronic use outside the hospital.
Single-Asset Commercial Focus
Savara's organization is structured around obtaining regulatory approvals and launching MOLBREEVI in the United States and Europe. The concentrated portfolio gives the company direct exposure to regulatory execution and adoption in a clearly defined rare-disease population.
Future catalysts
- U.K. MHRA decision on the MOLBREEVI marketing application in the fourth quarter of 2026.
- FDA PDUFA decision for MOLBREEVI on November 22, 2026.
- European Commission decision on the MOLBREEVI marketing authorization application in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Savara, Inc. (SVRA)?
Savara, Inc. (SVRA) most recently closed at 4.65 USD, a -2.72% move versus the previous session.
What is the market cap of Savara, Inc. (SVRA)?
Savara, Inc. currently has a market capitalization of 1.08B USD on BioPharmSignal.
What does Savara, Inc. do?
Rare Respiratory Disease Company Savara is focused on developing and preparing to commercialize a treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which surfactant accumulates in the alveoli and progressively impairs gas exchange. MOLBREEVI and Molgramostim MOLBREEVI is the proposed brand name for molgramostim inhalation...
On which exchange is SVRA stock listed?
Savara, Inc. (SVRA) is associated with NASDAQ, United States, Biopharma.
What is IMPALA-2?
The pivotal IMPALA-2 study evaluated effects on lung function, respiratory health, and disease burden.
Which conditions is Savara, Inc. targeting with IMPALA-2?
Savara, Inc. is associated with respiratory disease based on its company overview and current catalyst commentary.
How does Savara, Inc. describe recent progress with IMPALA-2?
U.K. MHRA decision on the MOLBREEVI marketing application in the fourth quarter of 2026. FDA PDUFA decision for MOLBREEVI on November 22, 2026. European Commission decision on the MOLBREEVI marketing authorization application in the first quarter of 2027.
What is Rare?
Rare Respiratory Disease Company Savara is focused on developing and preparing to commercialize a treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which surfactant accumulates in the alveoli and progressively impairs gas exchange.